Skip to main content

Table 3 Bispecific antibodies targeting CD47 and other molecular targets

From: Targeting CD47/SIRPα as a therapeutic strategy, where we are and where we are headed

Code Company/Research Team Target Structure IgG subclass Format
NI-1701 (TG-1801)a LightChain bioscience/TG Therapeutics CD47 × CD19 Fab+Fab with Fc, 1 + 1, κλ IgG1 one antibody arm (kappa) specific for CD47 and a second arm (lambda) specific to CD19, mesothelin or tumor associated antigen
IMM-0306a ImmuneOnco Biopharma CD47 × CD20 ligand+Fab with Fc, 2 + 2 IgG1 SIRPα V2-D1 infused with amino terminal of heavy chain of Rituximab
DVD-Ig SL/LL Ravindra Majeti’s lab in Stanford University CD47 × CD20 DVD-IgG IgG1 The amino terminus of each B6H12 variable domain infused to the carboxyl terminus of each 2B8 with linker”TVAAP”
SIRPa-gamma-CD20 HC CD47 × CD20 ligand+IgG IgG1 ligand located in Fab domain of intact aCD20 antibody(2B8, Rituximab)
CD20-2GL-SIRPa HC; CD20-4GL-SIRPa HC CD47 × CD20 ligand+IgG IgG1 ligand located in Fc domain of intact aCD20 antibody(2B8, Rituximab)
bi-scFv RTX-CD47 Wijnand Helfrich’s lab in Wijnand Helfrich CD47 × CD20 ScFV+ScFv,1 + 1 NA CD20-targeting scFv antibody fragment derived from rituximab fused in tandem to a CD47-blocking scFv
LQ007 Novamab CD47 × CD20 nanobody (C terminal) + IgG IgG4 nanobody from camel was fused to the carboxyl terminus of Rituximab
HMBD-004A Hummingbird bioscience CD47 × CD33 Fab+Fab with Fc, 1 + 1 IgG1 Humanized anti-CD47 variable domain as an effector arm and the gemtuzumab variable domain as an anti-CD33 or BCMA specificity arm.
HMBD-004B Hummingbird bioscience CD47 × BCMA Fab+Fab with Fc, 1 + 1 IgG1
NI-1801a Light Chain bioscience (Novimmune SA) CD47 × MSLN Fab+Fab with Fc,1 + 1,κλ IgG1 one arm target to CD47(kappa) and the other arm target to (lambda) mesothelin or tumor associated antigen
NI-2401 Light Chain bioscience (Novimmune SA) CD47 × TAA Fab+Fab with Fc,1 + 1,κλ Not Disclosed
NI-2601 Light Chain bioscience (Novimmune SA) CD47 × TAA Fab+Fab with Fc,1 + 1,κλ Not Disclosed
PT-886 Phanes Therapeutics CD47 × CLDN18.2 Fab+Fab with Fc, 1 + 1 Not Disclosed Not Disclosed
PT-796 Phanes Therapeutics CD47 × FRα Fab+Fab with Fc, 1 + 1 Not Disclosed Not Disclosed
PT-217 Phanes Therapeutics CD47 × DLL3 Fab+Fab with Fc, 1 + 1 Not Disclosed Not Disclosed
IMM-26011 ImmuneOnco Biopharma CD47 × FLT-3 ligand+Fab with Fc, 2 + 2 IgG1 SIRPa V2-D1 linked
IMM-2902 ImmuneOnco Biopharma CD47 × Her2 ligand+Fab with Fc,2 + 2 IgG1 SIRPa V2-D1 linked through a GS linker to amino terminal of light chain coding sequence of Herceptin (Trastuzumab)
SG3847 SUMGEN BIOTECH CD47 × CD38 ligand+Fab with Fc, 2 + 2 IgG1 SIRPa V1-D1 linked through a GS linker to amino terminal of light chain coding sequence of
HX-009a HanX Biopharmaceuticals CD47 × PD-1 ligand +Fab with Fc, 2 + 2 IgG4 amino terminal of extracellular region ligand (SIRPA V2D1) infused with carboxyl terminus of anti PD1 antibody (HX008)
IBI-322a Innovent CD47 × PD-L1 Fab+nanobody with Fc,1 + 2 Not Disclosed one arm target CD47 (Fab from IBI188), the other target is PDL1 (Bivalent nanobody)
BH-29XX Hanmi Pharmaceutical CD47 × PD-L1 Fab+Fab with Fc, 1 + 1 Not Disclosed Not Disclosed
? GenSci CD47 × PD-L1 Fab+Fv, KIH, 1 + 1 Not Disclosed one arm target CD47 (Fab from GenSci-059), the other target is PDL-1(Fv from GenSci-047)
PMC-122 PharmAbcine CD47 × PD-L1 Not Disclosed Not Disclosed Unknown
ABP-160 Abpro Therapeutics CD47 × PD-L1 Not Disclosed IgG1 wt Unknown
IMM-2505 ImmuneOnco Biopharma CD47 × PD-L1 ligand+Fab with Fc, 2 + 2 IgG1 SIRPa V2-D1 infused with amino terminal of heavy chain of antiPDL-1 antibody (Atezolizumab?)
TJ-L1C4 I-MAB Biopharma CD47 × PD-L1 Not Disclosed Not Disclosed PD-L1 antibody acts as the backbone and is linked with CD47 antibody
IAB Sinomab CD47× PD-L1 CV1(ALX148) + Fab with Fc IgG1/IgG4 variable region of atezolizumab and consensus variant 1 (CV1) monomer
SL-172154a Shattuck Labs CD47× CD40 ligand+ligand with Fc, 1 + 1 IgG1 ECDs of SIRPα and CD 40 L, adjoined by a central domain termed SIRPα-Fc-CD 40 L.
DSP107 Kahr Medical CD47 × 41BB ligand+ligand with Fc, 1 + 1 IgG1 human soluble SIRPα and 4-1BBL
TJ C4GM I-MAB Biopharma CD47 × CSF-2R IgG + fusion protein IgG1 or G4 Human GM-CSF was fused to the heavy chain C terminus of CD47 antibody
IMM-0207 ImmuneOnco Biopharma CD47× VEGF ligand+receptor with Fc, 2 + 2 IgG1 SIRPa V2-D1 linked via an Fc fragment of an Ig to an Ig region of an extracellular domain of VEGFR1D
  1. aantibody in clinical trial